-
Chou TC, 2006: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies[J]. Pharmacol Rev, 58, 621-681. doi: 10.1124/pr.58.3.10
-
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T, 2020: Compassionate use of remdesivir for patients with severe Covid-19[J]. N Engl J Med, 382, 2327-2336. doi: 10.1056/NEJMoa2007016
-
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X, 2020: Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor[J]. Nature, 581, 215-220. doi: 10.1038/s41586-020-2180-5
-
Lee C, 2019: Griffithsin, a highly potent broad-spectrum antiviral lectin from red algae: from discovery to clinical application[J]. Mar Drugs, 17, 567-. doi: 10.3390/md17100567
-
Li D, Jin M, Bao P, Zhao W, Zhang S, 2020: Clinical Characteristics and results of semen tests among men with coronavirus disease 2019[J]. JAMA, , e208292-.
-
Lusvarghi S, Bewley CA, 2016: Griffithsin: an antiviral lectin with outstanding therapeutic potential[J]. Viruses, 8, 296-. doi: 10.3390/v8100296
-
O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB, Palmer KE, Barnett BW, Meyerholz DK, Wohlford-Lenane CL, McCray PB Jr, 2010: Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae[J]. J Virol, 84, 2511-2521. doi: 10.1128/JVI.02322-09
-
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D, 2020: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 181, 281-292. doi: 10.1016/j.cell.2020.02.058
-
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G, 2020: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Res, 30, 269-271. doi: 10.1038/s41422-020-0282-0
-
Watanabe Y, Allen JD, Wrapp D, McLellan JS, Crispin M, 2020: Site-specific glycan analysis of the SARS-CoV-2 spike[J]. Science, 369, 330-333.
-
Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, Qi F, Bao L, Du L, Liu S, Qin C, Sun F, Shi Z, Zhu Y, Jiang S, Lu L, 2020: Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion[J]. Cell Res, 30, 343-355. doi: 10.1038/s41422-020-0305-x
-
Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CK, Wang Q, Du L, Tan W, Wilson IA, Jiang S, Yang B, Lu L, 2019: A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike[J]. Sci Adv, 5, eaav4580-. doi: 10.1126/sciadv.aav4580